Haematologica (Jan 2007)

Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin’s lymphoma

  • Armando Santoro,
  • Massimo Magagnoli,
  • Michele Spina,
  • Graziella Pinotti,
  • Licia Siracusano,
  • Mariagrazia Michieli,
  • Andrea Nozza,
  • Barbara Sarina,
  • Emanuela Morenghi,
  • Luca Castagna,
  • Umberto Tirelli,
  • Monica Balzarotti

DOI
https://doi.org/10.3324/haematol.10661
Journal volume & issue
Vol. 92, no. 1

Abstract

Read online

Background and Objectives Response to pre-transplant salvage chemotherapy remains the most important prognostic factor for outcome in refractory or relapsed Hodgkin’s lymphoma. Results of a new induction regimen are reported in terms of response rates, toxicity, and stem cell mobilization.Design and Methods Ninety-one patients with refractory or relapsed Hodgkin’s lymphoma were treated prospectively with a salvage regimen consisting of ifosfamide 2000 mg/m2 on days 1 to 4, gemcitabine 800 mg/m2 on days 1 and 4, vinorelbine 20 mg/m2 on day 1, and prednisolone 100 mg on days 1 to 4 (IGEV).Results Forty-nine patients (53.8%) achieved a complete remission and 25 (27.5%) a partial response for an overall response rate of 81.3%. In the multivariate analysis response to the last chemotherapy (p